HER2-Positive Breast Cancer Shows Strong Immune Response to Single Dose of Trastuzumab

HER2-Positive Breast Cancer Shows Strong Immune Response to Single Dose of Trastuzumab
Case Western University researchers found that a single dose of the anticancer drug trastuzumab induced a strong immune response in HER2-positive breast cancer tumors. Such results confirm previous research suggesting that intrinsic cancer subtype and immune cell infiltration predict response to trastuzumab-based therapy, and add to knowledge of antitumor immunity and patient response to treatment, as well as indicating potentially useful clinical HER2+ breast cancer biomarkers. The research paper, “Immune Signatures Following Single Dose Trastuzumab Predict Pathologic Response to Preoperative Trastuzumab and Chemotherapy in HER2-Positive Early Breast Cancer,” was published in Clinical Cancer Research. Trastuzumab (commercial name, Herceptin) is approved for use as a single or conjugation therapy for the treatment of HER2-positive adenocarcinoma of the stomach and gastroesophageal junction, and HER2-positive breast cancer. HER-2 (human epidermal growth factor receptor 2) is a cell-surface protein involved in the control of cell growth. HER2-positive is a term used to describe cancer cells that express high levels of this protein, leading to abnormal tumor growth and increased metastatic potential. Checking if a cancer is HER-2 positive can lead to a better planning of therapeutic strategies, including the administration of drugs that specifically kill HER-2 positive tumor cells. Previous research has suggested that the specific subtype of cancer and immune cell infiltration may help predict patie
Subscribe or to access all post and page content.